Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cefepime + doxycycline + vancomycin
- Development stage
- Preclinical
- Lead developer
- Bristol Myers Squibb
- Modality
- Small Molecules
- Administration
- Intravenous, Oral
01
Overview
This is a combination antibiotic therapy consisting of cefepime (a fourth-generation cephalosporin), doxycycline (a tetracycline antibiotic), and vancomycin (a glycopeptide antibiotic). This combination provides broad-spectrum coverage against various bacterial pathogens including Gram-positive, Gram-negative, and some atypical organisms. The combination has shown enhanced efficacy in treating certain infections compared to monotherapy with any of these antibiotics alone.
02
Targets
Beyond the preview
Go deeper on cefepime + doxycycline + vancomycin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cefepime + doxycycline + vancomycin.